英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
immunis查看　immunis　在百度字典中的解释百度英翻中〔查看〕
immunis查看　immunis　在Google字典中的解释Google英翻中〔查看〕
immunis查看　immunis　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Therapeutics targeting age-related disease - Immunis, Inc.
    Immunis is a clinical-stage biotechnology company targeting age-driven diseases to promote a healthier lifespan
  • Immunis Named by The Healthcare Technology Report as one of the “Top 50 . . .
    Immunis, Inc , a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, today announced it has been named one of the Top 50 Healthcare Technology Companies of 2025 by The Healthcare Technology Report, recognizing notable advances in next-generation therapeutics, care delivery and clinical insights The recognition follows
  • Immunis Licenses Treatment Candidate for Dyskinesia Associated with . . .
    Immunis, Inc , a clinical-stage biotech company targeting age-related diseases, today announced it has entered an exclusive licensing agreement with Toray to develop and commercialize a drug candidate for the treatment of dyskinesia associated with Parkinson’s disease Immunis will continue its development under the name “IMM02‑KORA” or “KORA ”
  • Immunis Named Among Top 25 Biotech Life Sciences Companies for 2025 . . .
    Immunis, Inc , a clinical-stage biotech pioneering multi-active stem cell-derived biologics for age and disease-related immune dysregulation, was honored as one of the “Top 25 Biotech Life Sciences Companies for 2025” by The Healthcare Technology Report This award is highly regarded by corporate executives, institutional investors, and industry leaders, cementing Immunis’ reputation
  • Clinical Trials for Age-Related Muscle Atrophy - Immunis, Inc.
    Immunis developed an investigational therapeutic (IMM01-STEM) derived from the secreted factors of human stem cells and is testing its efficacy in reversing age-related muscle atrophy in elderly adults and canines
  • Immunis Successfully Completes its Phase 1 2a Clinical Trial Targeting . . .
    Immunis, Inc , a clinical-stage biotech developing novel, multi-active biologics for age and disease-related immune dysregulation, is proud to announce the successful completion of its Phase 1 2a clinical trial The clinical study investigated the safety, tolerability, and preliminary efficacy of Immunis’ investigational therapy, IMM01-STEM, in reversing muscle atrophy in elderly individuals
  • Multi-active Biologics for Immune and Age-related Diseases - Immunis, Inc.
    Our multi-active biologics can potentially benefit the immune system, thereby improving the outlook on age and immune-related diseases
  • Immunis Closes $25 Million Series A-1 Financing Round
    Immunis, Inc , a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 financing round to fund two Phase 2 clinical trials Follow-on investments from all major existing investors, notably, Remiges Ventures, Continuum Health Ventures and BOLD Capital Partners were joined by new investments from LifeSpan





中文字典-英文字典  2005-2009